查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570960

鸦片类药物使用障碍（OUD）治疗市场：现况分析与预测（2024-2032）

Opioid Use Disorder (OUD) Treatment Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

鸦片类药物使用障碍（OUD）治疗市场，由于公司扩张，预计将以 8.1%左右的速度稳定成长。例如，2022年11月，Indivior PLC和Opiant Pharmaceuticals, Inc.宣布，Indivior将以每股20美元现金的预付款（总计约1.45亿美元）收购Opiant，收购期限为批准和推出后七年。公司已签订最终协议，以每股最高8 美元的或有价值收购该公司，在实现某些净收入里程碑时支付。本次交易已获得各公司董事会的一致批准。此次收购加强并扩大了 Indivior 作为成瘾治疗领域领导者的地位。此外，健康和保健趋势的上升、治疗中心数量的增加、与康復机构的合併以及政府对鸦片类药物使用障碍的认识和治疗的努力和资金的增加推动鸦片类药物使用障碍（OUD）治疗市场的成长。

依药物类别，市场分为buprenorphine、methadone和naltrexone。buprenorphine在2023年拥有最高的市场占有率，因为与其他治疗药物相比，它具有更高的疗效和更少的副作用。buprenorphine属于部分鸦片类促效剂家族，因其滥用和过量的可能性较低且有助于控制烟瘾和戒断症候群而受到高度重视。由于处方者和患者的接受度以及允许其分布的监管因素，buprenorphine的使用日益增加。此外，缓释製剂和联合製剂等先进功能改善Welch的治疗方案并促进市场成长。将buprenorphine纳入治疗方案并提高其对抗鸦片类药物使用障碍的有效性的持续努力进一步推动了这一领域的成长。

依给药途径，市场分为经口药物和非口药药物。由于经口製剂方便、有效且价格实惠，预计在预测期内将占据重要的市场占有率。buprenorphine和naltrexone都是经口药物，且是非侵入性的，因此患者不必经常去医生办公室接受药物。新分子和改进的药物递送系统，例如缓释製剂和组合製剂，提供更大的功效和安全优势。其他因素也起到了一定作用，例如治疗方案中经口药物的普遍接受度以及临床医生和患者意识的提高。这种成长反映了这样一个事实：经口药物对于製定 OUD 管理实用且有效的治疗策略非常重要。因此，预计在预测期内，经口药物部分将在给药途径中占据重要的市场占有率。

根据通路，市场分为医院药房、零售药房/商店和网路药房。市场区隔 由于消费者的存取选项、舒适度和匿名性不断增加，线上药局市场稳步成长。科技的进步使得透过数位健康平台、远距医疗和线上药局更容易获得 OUD 处方和药物，使患者能够在舒适的家中私下管理自己的症状。该细分市场进一步受益于改进的资料保护、更快的处方方法以及对以前未提供服务的区域的可及性。线上药局增加远距医疗服务和电子处方也透过扩大其在提供维持护理和持续药物管理方面的作用，促进了该行业的成长。因此，预计线上药局产业在预测期内的通路将显着成长。

为了更了解鸦片类药物使用疾患（OUD）治疗药物的市场导入，市场根据北美 (美国、加拿大、北美其他地区) 、欧洲 (德国、法国、英国、西班牙、义大利、欧洲其他地区) 、亚太地区 (中国、日本、印度、亚太其他地区) 和世界其他国家的全球布局进行分析。由于鸦片类药物流行的持续增加以及对治疗方案的了解不断加深，北美将在2023年占据大部分市场占有率。该市场受到药物辅助治疗（MAT）需求不断成长的推动，其中包括行为疗法以及buprenorphine和methadone。此外，市场上新配方和治疗方法的出现也被认为推动该领域的市场成长。进一步推动市场扩张的其他因素包括政府活动、增加药物滥用治疗服务的资金以及全球向多模式医疗保健的转变。例如，2023年5月，美国食品药物管理局核准Brixadi（buprenorphine）缓释注射液用于皮下用途，用于治疗中重度鸦片类药物使用障碍（OUD）。 Brixadi 是一种每週一次的注射剂，可用于开始接受单剂量经黏膜buprenorphine治疗或已经接受buprenorphine治疗的患者，对于已经接受buprenorphine治疗的患者，有两种剂型。可以每月注射一次。这样一来，2023年北美将在所有地区中占据较大的市场占有率。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长强度
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势
  • PESTEL 分析
  • 需求方分析
  • 供给面分析
    • 併购
    • 投资场景
    • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

  • 依地区价格分析
  • 影响价格的因素

第6章 全球鸦片类药物使用障碍（OUD）治疗市场收入，2022-2032年

第7章 市场洞察：依药物类别

  • buprenorphine
  • methadone
  • naltrexone

第8章 市场洞察：依给药途径

  • 经口
  • 非经口

第9章 市场洞察：依通路

  • 医院药房
  • 零售药局/商店
  • 网路药局

第10章 市场洞察：依地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 世界其他地区

第11章 鸦片类药物使用疾患（OUD）治疗状态

第12章 价值链分析

  • 边际分析
  • 进入市场的公司名单

第13章 竞争态势

  • 竞争仪表板
  • 竞争市场定位分析
  • 波特五力分析

第14章 公司简介

  • MediciNova, Inc.
  • Aphios Corporation
  • Braeburn Inc.
  • Alkermes
  • Indivior PLC
  • Zynerba Pharmaceuticals, Inc.
  • Mylan N.V.
  • Janssen Global Services, LLC
  • Sandoz AG
  • Cumberland Pharmaceuticals Inc.

第15章 缩写与先决条件

第16章 附录

简介目录
Product Code: UMHE213007

Opioid Use Disorder (OUD) requires medication, behavioral therapies, and supportive services for those struggling with addiction since it is a complex disease affecting the brain. Medications like methadone, buprenorphine, and naltrexone alleviate the withdrawal process and provide relief from cravings and opioid effects. Other behavioral therapies such as cognitive behavioral therapy and contingency management seek to change undesirable behaviors as well as incentivize recovery. Counseling, case management, and support groups help individuals continue to abstain from substance use and reintegrate into society. Holistic non-pharmacological approaches that exist include medication-assisted treatment (MAT) programs and OUD treatment strategies that are aimed at providing a rounded and comprehensive solution to treat the disorder.

The Opioid Use Disorder (OUD) Treatment Market is expected to grow at a steady rate of around 8.1% owing to the rising company expansions. For instance, in November 2022, Indivior PLC and Opiant Pharmaceuticals, Inc. entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of USD 20.00 per share, in cash (approximately USD 145 million in aggregate), plus up to USD 8.00 per share in contingent value rights that may become payable if certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the board of directors of each company. The acquisition strengthened and extended the Indivior's position as a leader in addiction treatment. Moreover, the rising health & wellness trends, a growing number of treatment centers, mergers with recovery institutions, and increasing initiatives & funding by the government for the awareness and treatment of opioid use disorder are leading to the growth of the opioid use disorder (OUD) treatment market.

Based on the drug class, the market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment held a significant market share in the market in the year 2023 owing to its effectiveness and side effects as compared to other treatment solutions. Buprenorphine belongs to the partial opioid agonist, and it is appreciable because it helps in managing craving and withdrawal syndrome with a low likelihood of abuse and overdose. The increased use of buprenorphine is due to the acceptance of prescribers and patients as well as regulatory factors that allow its distribution. Moreover, advanced features like extended-release formulations and combination products are improving the therapeutic profile of Welch and fueling the market's growth. The growth of this segment is further supported by the continuation of the efforts to incorporate buprenorphine into the treatment plans and enhance the efficacy in combating opioid use disorders.

Based on the route of administration, the market is bifurcated into oral and parenteral. The oral segment is expected to hold a significant market share in the forecast period as it is convenient, effective, and affordable. Both buprenorphine and naltrexone are orally administered drugs and are not invasive so patients do not have to constantly visit the clinic to receive this medication. New molecules have improved drug delivery systems including extended-release products and combination products have given them a further edge in terms of efficacy and safety. Other factors such as the general acceptance of oral medications in treatment protocols along with the growing realization on the part of clinicians and patients have also contributed. This growth reflects the fact that the oral segment has been highly important for the development of practical and effective treatment strategies for OUD management. Thus, the oral segment is expected to hold a significant market share in the forecast period among the route of administration methods.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & stores, and online pharmacies. The online pharmacies segment of the opioid use disorder (OUD) treatment market has witnessed robust growth owing to enhanced access options, comfort, and anonymity for consumers. Due to the advancement in technology, prescriptions and medications for OUD have been made more easily available through digital health platforms, telemedicine, and online pharmacies making it easy for the patients to deal with their conditions away from the public eye and in the comfort of their homes. This segment has been further benefiting from improved data protection, faster prescription methods, and accessibility to areas not previously served. Also, the inclusion of online pharmacies with telehealth services and electronic prescriptions has broadened their role in the provision of maintenance care and continuous medication management, which also has aided in the growth of this sector. Thus, the online pharmacies segment is expected to grow at a significant rate in the forecast period among the distribution channels.

For a better understanding of the market adoption of opioid use disorder (OUD) treatments, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the majority share of the market in the year 2023 because of the continuous increase in the opioid epidemic and a greater understanding of treatment programs. This market is boosted by increased demand for medication-assisted treatments (MAT), including buprenorphine and methadone as well as behavioral therapies. The arrival of new drug formulations and therapies in the market is also credited to have fueled market growth in this segment. Some of the other factors that are further driving market expansion include government campaigns, increasing funding for substance abuse treatment services, and global transitions towards combined care practices. For instance, in May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine. Thus, amongst areas, North America held a significant share of the market in the year 2023.

Some of the major players operating in the market include MediciNova, Inc.; Aphios Corporation; Braeburn Inc.; Alkermes; Indivior PLC; Zynerba Pharmaceuticals, Inc.; Mylan N.V.; Janssen Global Services, LLC; Sandoz AG; Cumberland Pharmaceuticals Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Opioid Use Disorder (OUD) Treatment Market
  • 2.2. Research Methodology of the Opioid Use Disorder (OUD) Treatment Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL OPIOID USE DISORDER (OUD) TREATMENT MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DRUG CLASS

  • 7.1. Buprenorphine
  • 7.2. Methadone
  • 7.3. Naltrexone

8.MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1. Oral
  • 8.2. Parenteral

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies & Stores
  • 9.3. Online Pharmacies

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. India
    • 10.3.3. Japan
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of the World

11.TREATMENT LANDSCAPE OF OPIOID USE DISORDER

12.VALUE CHAIN ANALYSIS

  • 12.1. Marginal Analysis
  • 12.2. List of Market Participants

13.COMPETITIVE LANDSCAPE

  • 13.1. Competition Dashboard
  • 13.2. Competitor Market Positioning Analysis
  • 13.3. Porter Five Forces Analysis

14.COMPANY PROFILES

  • 14.1. MediciNova, Inc.
    • 14.1.1. Company Overview
    • 14.1.2. Key Financials
    • 14.1.3. SWOT Analysis
    • 14.1.4. Product Portfolio
    • 14.1.5. Recent Developments
  • 14.2. Aphios Corporation
  • 14.3. Braeburn Inc.
  • 14.4. Alkermes
  • 14.5. Indivior PLC
  • 14.6. Zynerba Pharmaceuticals, Inc.
  • 14.7. Mylan N.V.
  • 14.8. Janssen Global Services, LLC
  • 14.9. Sandoz AG
  • 14.10. Cumberland Pharmaceuticals Inc.

15.ACRONYMS & ASSUMPTION

16.ANNEXURE